Gossamer Bio, Inc.
https://www.gossamerbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gossamer Bio, Inc.
Aerovate Tanks On Trial Catastrophe
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: AstraZeneca’s Vaxzevria farewell; the next wave of cardiometabolics; Pfizer recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer partners up for respiratory therapy.
Gossamer Partners With Chiesi To Accelerate Seralutinib Development
Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.
Keeping Up The Pressure In Pulmonary Arterial Hypertension
Merck & Co leads a market expected to exceed $10bn by 2028, but others are aiming to muscle in.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AA BioPharma Inc.
- Adhaere Pharmaceuticals, Inc.
- GB006, Inc.
- Pulmagen Therapeutics LLP
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice